These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 19348557)

  • 1. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress with human H5N1 vaccines: a perspective from industry.
    Palache B; Krause R
    Expert Rev Vaccines; 2009 Apr; 8(4):391-400. PubMed ID: 19348556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].
    Loulergue P; Launay O
    Med Sci (Paris); 2009; 25(8-9):719-25. PubMed ID: 19765386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
    Hasegawa H; Ichinohe T; Tamura S; Kurata T
    Expert Rev Vaccines; 2007 Apr; 6(2):193-201. PubMed ID: 17408369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
    Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
    Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of vaccines against influenza A virus (H5N1).
    Li WC; Huang YC
    Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
    Keitel WA; Atmar RL
    Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
    Carter NJ; Plosker GL
    BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing vaccines against pandemic influenza.
    Wood JM
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1953-60. PubMed ID: 11779397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.
    Leroux-Roels G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.